医薬品販売受託機関の世界市場

医薬品販売受託機関の世界市場は2030年までに158億米ドルに達する見込み

2024年に106億米ドルと推定される医薬品販売受託機関の世界市場は、2024年から2030年にかけてCAGR 6.8%で成長し、2030年には158億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるパーソナルプロモーションは、CAGR 5.6%を記録し、分析期間終了時には96億米ドルに達すると予測されます。非パーソナルプロモーション分野の成長率は、分析期間でCAGR 8.9％と推定されます。

米国市場は29億米ドル、中国はCAGR 10.5％で成長すると予測

米国の医薬品販売受託機関市場は、2024年には29億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに33億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.5％と6.6％と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の医薬品CRO市場- 主要動向と促進要因のまとめ

医薬品CROとは何か？

医薬品開発業務受託機関（CRO）とは、製薬、バイオテクノロジー、医療機器業界に委託研究サービスを提供する企業です。これらのサービスには、臨床試験管理、医薬品開発、規制コンプライアンス、ラボ試験などが含まれます。CROは、臨床試験のデザイン、実施、分析において製薬会社をサポートし、多くの場合、初期段階の研究から市場開拓まで、医薬品開発の運営面を担当します。

製薬CROは、製薬会社が専門知識を利用し、コストを削減し、医薬品開発期間を短縮することで、業界に利益をもたらします。CROにアウトソーシングすることで、製薬会社は創薬などのコアコンピタンスに集中できる一方、CROの業務や技術に関する専門知識を活用することで、より効率的な開発プロセスを実現することができます。CROはまた、患者募集、規制遵守、データ解析など、複雑な臨床試験の管理も支援し、医薬品開発プロジェクトが必要な科学的・規制的基準を満たすようにします。CROと提携することで、製薬会社は複雑化し、高額化する医薬品開発の情勢を、より機敏に、より低い投資リスクで乗り切ることができます。

なぜ医薬品CRO市場は拡大しているのか？

製薬企業の研究開発費の増加、アウトソーシングサービスに対する需要の高まり、臨床試験の複雑化など、いくつかの重要な要因により製薬CRO市場は拡大しています。市場成長の主な促進要因の1つは、製薬企業による研究開発（R&D）投資の増加です。製薬業界が革新的な新薬開発へのプレッシャーの高まりに直面する中、研究開発費は増加し、CROサービスへの需要を牽引しています。CROは、臨床試験、製剤化、薬事申請など、専門知識を必要とする研究開発プロジェクトの管理・遂行において、製薬企業を支援する重要な役割を担っています。

アウトソーシングの動向も、製薬CRO市場の拡大に寄与する重要な要因の一つです。製薬会社は、業務コストの削減と効率化を図るため、外部のサービスプロバイダーを活用する傾向が強まっています。臨床試験、臨床検査、薬事などの非中核業務をアウトソーシングすることで、製薬企業は創薬や商業化などのコアコンピタンスに集中することができます。また、アウトソーシングを利用することで、社内にインフラを構築することなく、事業を迅速に拡大し、専門的な知識を利用することができます。このようなアウトソーシングへのシフトは、CROサービスに対する需要を大幅に増加させ、市場の成長を牽引しています。

臨床試験の複雑化も市場拡大の原動力となっています。個別化医薬品の需要増加、国際共同治験の必要性、生物製剤や遺伝子治療の台頭などの要因により、臨床試験は複雑化しています。CROは、患者募集、試験デザイン、法規制遵守、世界・ロジスティクスなどの分野で専門知識を提供し、こうした複雑性を管理するのに適しています。臨床試験が進化するにつれ、製薬会社はますます複雑化する医薬品開発プロセスをナビゲートするためにCROへの依存度を高めており、これが医薬品CRO市場の成長にさらに寄与しています。

医薬品CRO市場の将来を形作る主要動向とは？

個別化医療への注目の高まり、臨床試験技術の進歩、戦略的パートナーシップの台頭など、いくつかの主要動向が医薬品CRO市場の将来を形成しています。最も重要な動向のひとつは、個別化医療への需要の高まりです。製薬企業が特定の患者集団や遺伝子プロファイルに合わせた治療を開発する傾向が強まるにつれ、専門的な臨床試験や個別化された医薬品開発プロセスの必要性が高まっています。CROは、バイオマーカー検査、遺伝子プロファイリング、臨床試験における患者の層別化など、精密医療に焦点を当てたサービスを提供することで、この傾向に適応しています。このような個別化治療へのシフトは、今後も製薬CRO市場の将来を形作るものと予想され、各社は個別化治療の需要に対応するため、より専門的なソリューションを提供しています。

臨床試験技術の進歩も医薬品CRO市場の将来に影響を与えています。データ分析、人工知能（AI）、ウェアラブルデバイスなどのデジタル技術の活用は、臨床試験のデザインと実施に革命をもたらしています。CROはこれらのテクノロジーを採用することで、患者募集の強化、臨床試験モニタリングの改善、従来の臨床試験に伴うコストと時間の削減を図っています。例えば、AIは患者データの解析や臨床転帰の予測に活用されており、ウェアラブル端末は患者の健康状態をリアルタイムでモニタリングし、データ収集と試験の効率化を支援します。こうした技術の進歩により、臨床試験の効果とスピードが大幅に向上し、医薬品CRO市場の成長がさらに促進されると期待されています。

製薬企業とCROの戦略的パートナーシップの台頭も、市場の将来を形作る重要な動向です。多くの製薬企業は、研究開発能力の強化、イノベーションの向上、新薬の市場投入期間の短縮を目的として、CROと長期的な提携関係を結んでいます。このような提携により、製薬企業はCROの臨床試験管理、規制遵守、データ分析などの専門知識を活用できる一方、CROにはより安定した収益源を提供できるようになります。新薬開発の複雑さが増すにつれ、戦略的パートナーシップはより一般的になり、製薬CROサービスの需要はさらに高まると予想されます。

医薬品CRO市場の成長促進要因は？

医薬品CRO市場の成長は、研究開発サービスに対する需要の増加、医薬品開発の複雑化、新興国市場の台頭など、いくつかの要因によってもたらされます。主な要因の一つは、研究開発サービスに対する需要の増加です。製薬会社が革新的な新薬の開発に注力し続ける中、外部の研究開発専門家に対するニーズが高まっています。CROは、臨床試験のデザイン・管理、薬事申請、ラボ試験に必要な専門知識とインフラを提供し、医薬品開発プロセスにおける貴重なパートナーとなっています。新薬の迅速かつ効率的な市場投入への注目が高まるにつれ、研究開発サービスのアウトソーシングに対する需要が高まっており、これが医薬品CRO市場の成長を後押ししています。

医薬品開発の複雑化も市場成長の主な要因です。生物製剤、遺伝子治療、個別化医療の台頭により、臨床試験はより複雑化し、専門的な知識、技術、専門知識が必要となっています。CROは、患者募集からデータ収集、規制遵守、試験モニタリングに至るまで、医薬品開発の複雑性を管理する上で不可欠なパートナーと見なされるようになっています。医薬品開発が複雑化するにつれ、製薬会社はこれらの課題を解決するためにCROへの依存度を高めており、CROのサービスへの需要が高まっています。

新興市場の台頭も医薬品CRO市場の成長に寄与しています。多くの製薬企業が、アジア太平洋、ラテンアメリカ、アフリカなどの新興市場に研究開発および臨床試験事業を拡大しています。これらの地域は、人口が多く多様性に富み、運営コストが比較的低く、規制環境も進化しているため、臨床試験にとって大きなチャンスとなります。世界の能力を持つCROは、これらの地域の製薬企業をサポートするのに適した立場にあり、臨床試験ネットワークの拡大や新市場への参入を支援しています。新興市場への医薬品研究開発の拡大は、CROサービスに対する需要を促進し、市場成長をさらに後押ししています。

最後に、製薬業界におけるコスト抑制傾向の高まりも市場成長の促進要因です。製薬会社は、高い品質水準とコンプライアンスを維持しつつ、コスト削減と効率化を図る必要に迫られています。研究開発機能をCROにアウトソーシングすることで、製薬企業は運営コストを削減し、インフラへの大規模な設備投資を回避し、専門的な知識を得ることができます。このようなコスト抑制の動向は、イノベーションと規制遵守を高い水準で維持しながら、研究開発プロセスの最適化を目指す製薬企業にとって、今後も医薬品CRO市場の成長を牽引するものと思われます。

セグメント

サービス（パーソナル・プロモーション、ノン・パーソナル・プロモーション）;治療領域（がん、循環器、神経、感染症、代謝疾患、整形外科疾患、その他）;エンドユーザー（製薬企業、バイオ医薬品企業）

調査対象企業の例

• Amplity Health
• Axxelus
• CMIC Holdings Co., Ltd.
• EPS Corporation
• EVERSANA
• ICON plc
• InVentiv Health
• IQVIA, Inc.
• MaBico
• Mednext Pharma Pvt. Ltd.
• PDI, Inc.
• Peak Pharma Solutions Inc.
• PharmaForce International
• PharmaLex
• Promoveo Health
• Publicis Touchpoint Solutions
• QFR Solutions
• Sales Focus Inc
• Sinco Pharma
• Syneos Health

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Pharmaceutical Contract Sales Organizations Market to Reach US$15.8 Billion by 2030

The global market for Pharmaceutical Contract Sales Organizations estimated at US$10.6 Billion in the year 2024, is expected to reach US$15.8 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Personal Promotion, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$9.6 Billion by the end of the analysis period. Growth in the Non-personal promotion segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 10.5% CAGR

The Pharmaceutical Contract Sales Organizations market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 10.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Pharmaceutical CRO Market - Key Trends & Drivers Summarized

What Is a Pharmaceutical CRO and How Does It Benefit the Industry?

A Pharmaceutical Contract Research Organization (CRO) is a company that provides outsourced research services to the pharmaceutical, biotechnology, and medical device industries. These services include clinical trial management, drug development, regulatory compliance, laboratory testing, and more. CROs support pharmaceutical companies in the design, implementation, and analysis of clinical trials, often handling the operational aspects of drug development, from early-stage research through to market launch.

Pharmaceutical CROs benefit the industry by allowing pharmaceutical companies to access specialized expertise, reduce costs, and speed up drug development timelines. Outsourcing to CROs helps pharmaceutical companies focus on their core competencies, such as drug discovery, while leveraging the operational and technical expertise of CROs for more efficient development processes. CROs also help manage the complexities of clinical trials, including patient recruitment, regulatory compliance, and data analysis, ensuring that drug development projects meet the necessary scientific and regulatory standards. By partnering with CROs, pharmaceutical companies can navigate the increasingly complex and expensive landscape of drug development with more agility and lower investment risk.

Why Is the Pharmaceutical CRO Market Expanding?

The pharmaceutical CRO market is expanding due to several key factors, including increasing R&D spending by pharmaceutical companies, the rising demand for outsourced services, and the growing complexity of clinical trials. One of the major drivers of market growth is the rising investment in research and development (R&D) by pharmaceutical companies. As the pharmaceutical industry faces increasing pressure to develop new and innovative drugs, R&D spending has been rising, driving demand for CRO services. CROs play a vital role in helping pharmaceutical companies manage and execute R&D projects, including clinical trials, drug formulation, and regulatory submissions, all of which require specialized expertise.

The growing trend of outsourcing is another key factor contributing to the expansion of the pharmaceutical CRO market. Pharmaceutical companies are increasingly looking to external service providers to reduce operational costs and improve efficiency. By outsourcing non-core activities such as clinical trials, laboratory testing, and regulatory affairs, pharmaceutical companies can focus on their core competencies, such as drug discovery and commercialization. Outsourcing also allows companies to scale operations quickly and access specialized expertise without the need to build internal infrastructure. This shift toward outsourcing has significantly increased the demand for CRO services, driving the growth of the market.

The growing complexity of clinical trials is also driving the market’s expansion. Clinical trials are becoming more complex due to factors such as the increasing demand for personalized medicines, the need for international trials, and the rise of biologics and gene therapies. CROs are better equipped to manage these complexities, offering expertise in areas such as patient recruitment, trial design, regulatory compliance, and global logistics. As clinical trials evolve, pharmaceutical companies are relying more on CROs to navigate the increasingly intricate process of drug development, which is further contributing to the growth of the pharmaceutical CRO market.

What Key Trends Are Shaping the Future of the Pharmaceutical CRO Market?

Several key trends are shaping the future of the pharmaceutical CRO market, including the growing focus on personalized medicine, advancements in clinical trial technology, and the rise of strategic partnerships. One of the most significant trends is the growing demand for personalized medicine. As pharmaceutical companies increasingly develop treatments tailored to specific patient populations or genetic profiles, the need for specialized clinical trials and personalized drug development processes is rising. CROs are adapting to this trend by offering services that focus on precision medicine, including biomarker testing, genetic profiling, and patient stratification in clinical trials. This shift towards personalized treatments is expected to continue shaping the future of the pharmaceutical CRO market, with companies offering more specialized solutions to meet the demands of personalized therapies.

Advancements in clinical trial technology are also influencing the future of the pharmaceutical CRO market. The use of digital technologies, such as data analytics, artificial intelligence (AI), and wearable devices, is revolutionizing clinical trial design and execution. CROs are adopting these technologies to enhance patient recruitment, improve trial monitoring, and reduce the costs and time associated with traditional clinical trials. For example, AI is being used to analyze patient data and predict clinical outcomes, while wearable devices help monitor patient health in real-time, improving data collection and trial efficiency. These technological advancements are expected to significantly improve the effectiveness and speed of clinical trials, further driving the growth of the pharmaceutical CRO market.

The rise of strategic partnerships between pharmaceutical companies and CROs is another key trend shaping the market’s future. Many pharmaceutical companies are entering long-term collaborations with CROs to enhance their R&D capabilities, improve innovation, and speed up the time-to-market for new drugs. These partnerships allow pharmaceutical companies to tap into the CRO’s expertise in clinical trial management, regulatory compliance, and data analysis while providing CROs with more stable revenue streams. As the complexity of drug development increases, strategic partnerships are expected to become more common, further boosting the demand for pharmaceutical CRO services.

What Are the Key Drivers of Growth in the Pharmaceutical CRO Market?

The growth in the pharmaceutical CRO market is driven by several factors, including the increasing demand for R&D services, the growing complexity of drug development, and the rise of emerging markets. One of the primary drivers is the increasing demand for research and development services. As pharmaceutical companies continue to focus on developing new and innovative therapies, the need for external R&D expertise has grown. CROs offer the specialized knowledge and infrastructure required for the design and management of clinical trials, regulatory submissions, and laboratory testing, making them valuable partners in the drug development process. The increasing focus on bringing new drugs to market quickly and efficiently is driving the demand for outsourced R&D services, which is fueling the growth of the pharmaceutical CRO market.

The growing complexity of drug development is another key driver of market growth. With the rise of biologics, gene therapies, and personalized medicine, clinical trials are becoming more intricate, requiring specialized knowledge, technology, and expertise. CROs are increasingly seen as essential partners in managing the complexities of drug development, from patient recruitment and data collection to regulatory compliance and trial monitoring. As drug development becomes more complex, pharmaceutical companies are relying more on CROs to navigate these challenges, driving demand for their services.

The rise of emerging markets is also contributing to the growth of the pharmaceutical CRO market. Many pharmaceutical companies are expanding their R&D and clinical trial operations into emerging markets such as Asia-Pacific, Latin America, and Africa. These regions offer significant opportunities for clinical trials due to their large, diverse populations, relatively lower operational costs, and evolving regulatory environments. CROs with global capabilities are well-positioned to support pharmaceutical companies in these regions, helping them expand their clinical trial networks and access new markets. The expansion of pharmaceutical R&D into emerging markets is driving the demand for CRO services, further fueling market growth.

Lastly, the growing trend of cost containment in the pharmaceutical industry is another driver of market growth. Pharmaceutical companies are under increasing pressure to reduce costs and improve efficiency while maintaining high standards of quality and compliance. By outsourcing R&D functions to CROs, pharmaceutical companies can lower operational costs, avoid large capital investments in infrastructure, and gain access to specialized expertise. This trend toward cost containment is likely to continue driving the growth of the pharmaceutical CRO market as companies seek to optimize their R&D processes while maintaining high levels of innovation and regulatory compliance.

SCOPE OF STUDY:

The report analyzes the Pharmaceutical Contract Sales Organizations market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Services (Personal Promotion, Non-personal promotion); Therapeutic Areas (Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases, Others); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Amplity Health
• Axxelus
• CMIC Holdings Co., Ltd.
• EPS Corporation
• EVERSANA
• ICON plc
• InVentiv Health
• IQVIA, Inc.
• MaBico
• Mednext Pharma Pvt. Ltd.
• PDI, Inc.
• Peak Pharma Solutions Inc.
• PharmaForce International
• PharmaLex
• Promoveo Health
• Publicis Touchpoint Solutions
• QFR Solutions
• Sales Focus Inc
• Sinco Pharma
• Syneos Health

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Pharmaceutical Contract Sales Organizations - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Need for Agile, Cost-Efficient Commercialization Models Spurs Outsourcing of Sales Operations to CSOs
  • Expansion of Specialty Pharma and Orphan Drug Pipelines Fuels Demand for Highly Targeted, Trained Sales Forces
  • Pressure to Optimize Fixed Costs in Commercial Operations Encourages Pharma to Embrace CSO Flexibility
  • Growing Use of Patient-Centric and Outcome-Based Sales Models Increases Need for Customizable CSO Solutions
  • Pharma M&A and Product Divestments Create Opportunities for Interim or Transitional CSO Support
  • Increasing Emphasis on HCP Education and KOL Engagement Drives Demand for Clinically Skilled Field Reps
  • Expansion of Market Access and Field Reimbursement Teams Elevates Strategic Role of CSOs Beyond Promotion
  • Data Analytics Integration in Field Sales Programs Enhances Territory Targeting and ROI Measurement
  • Emergence of Multichannel and Omnichannel Promotion Strategies Requires Cross-Functional CSO Expertise
  • Rising Complexity of Launch Environments Fuels Demand for CSOs That Offer Pre-Launch and Post-Launch Support
  • Access Challenges and Prescriber Fatigue Spur Growth in CSO-Based Inside Sales and Non-Personal Promotion Models
  • Smaller Biotech Firms Without In-House Sales Infrastructure Depend on CSOs for Rapid Market Entry
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pharmaceutical Contract Sales Organizations Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pharmaceutical Contract Sales Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Personal Promotion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Personal Promotion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Personal Promotion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Non-personal promotion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Non-personal promotion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Non-personal promotion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Orthopedic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Orthopedic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Orthopedic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• JAPAN
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• CHINA
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• EUROPE
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Pharmaceutical Contract Sales Organizations by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• FRANCE
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• GERMANY
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Pharmaceutical Contract Sales Organizations by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• INDIA
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Pharmaceutical Contract Sales Organizations by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Pharmaceutical Contract Sales Organizations by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030
• AFRICA
  • Pharmaceutical Contract Sales Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Pharmaceutical Contract Sales Organizations by Services - Personal Promotion and Non-personal promotion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Services - Percentage Breakdown of Value Sales for Personal Promotion and Non-personal promotion for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Pharmaceutical Contract Sales Organizations by End-Use - Pharmaceutical Companies and Biopharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Pharmaceutical Contract Sales Organizations by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies and Biopharmaceutical Companies for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Pharmaceutical Contract Sales Organizations by Therapeutic Areas - Percentage Breakdown of Value Sales for Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders, Orthopedic Diseases and Others for the Years 2015, 2025 & 2030

IV. COMPETITION